Results 71 to 80 of about 696,003 (270)

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries

Open Forum Infectious Diseases, 2019
Background Rotavirus causes morbidity and mortality in children particularly in low-income countries (LICs) and lower-middle-income countries (LMICs).
S. Haider, U. Chaikledkaew, M. Thavorncharoensap, S. Youngkong, M. Islam, A. Thakkinstian   +5 more
semanticscholar   +1 more source

Measurement of coverage, compliance and determinants of uptake in a publicly funded rotavirus vaccination programme: a retrospective cohort study

BMJ Open, 2019
Objectives In June 2015, Alberta, Canada instituted a universal publicly funded rotavirus vaccination programme (Rotarix, RV1), with vaccine doses scheduled for 2 and 4 months of age.
Lawrence W Svenson, Ellen Rafferty, Xiaoyan Guo, Bruce McDonald, Shannon Elizabeth MacDonald   +4 more
doaj   +1 more source

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money, Erin Sullivan, Hannah Rector, Corrie E. McDaniel, Jessica L. Markham, Mersine A. Bryan   +5 more
wiley   +1 more source

Effectiveness of Monovalent Rotavirus Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan Children

Clinical Infectious Diseases, 2019
Background Rotavirus remains a leading cause of pediatric diarrheal illness and death worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014.
S. Khagayi, R. Omore, G. Otieno, B. Ogwel, J. B. Ochieng, J. Juma, Evans Apondi, G. Bigogo, C. Onyango, Mwanajuma Ngama, Regina Njeru, B. Owor, M. Mwanga, Y. Addo, C. Tabu, A. Amwayi, J. Mwenda, J. Tate, U. Parashar, R. Breiman, D. Nokes, D. Nokes, J. Verani   +22 more
semanticscholar   +1 more source

Characterization of Rotavirus Infection in Hospitalized Children under 5 with Acute Gastroenteritis 5 Years after Introducing the Rotavirus Vaccines in South Korea

Children, 2022
We herein characterized rotavirus infection in hospitalized children under 5 years of age with gastroenteritis after introducing rotavirus vaccines in South Korea from 20 February 2012, to 31 March 2013.
Hye Sun Yoon, Yong-Hak Sohn, Jeong Don Chae, Jiseun Lim, Seung Yeon Kim   +4 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Rotavirus vaccine impact assessment surveillance in India: protocol and methods

BMJ Open, 2019
Introduction Rotavirus infection accounts for 39% of under-five diarrhoeal deaths globally and 22% of these deaths occur in India. Introduction of rotavirus vaccine in a national immunisation programme is considered to be the most effective intervention ...
N. Nair, S. Reddy N, S. Giri, V. Mohan, U. Parashar, J. Tate, Minesh P Shah, R. Arora, M. Gupte, S. Mehendale, G. Kang   +10 more
semanticscholar   +1 more source

Rotavirus Vaccines: an Overview [PDF]

Clinical Microbiology Reviews, 2008
SUMMARY Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. Vaccination is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus ...
openaire   +2 more sources

Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

, 2014
RIX4414 (Rotarix (TM)), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year.
Phua, Kong Boo;Lim, Fong Seng;Lau, Yu Lung;Nelson, Edmund Anthony Severn;Huang, Li Min;Quak, Seng Hock;Lee, Bee Wah;van Doorn, Leen Jan;Teoh, Yee Leong;Tang, Haiwen;Suryakiran, P. V.;Smolenov, Igor V.;Bock, Hans L.;Han, Htay Htay, 黃立民   +1 more
core   +1 more source